Cargando…
The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function
BACKGROUND: Multimorbidity (the presence of two or more chronic conditions) is common amongst people with chronic kidney disease, but it is unclear which conditions cluster together and if this changes as kidney function declines. We explored which clusters of conditions are associated with differen...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623942/ https://www.ncbi.nlm.nih.gov/pubmed/36320059 http://dx.doi.org/10.1186/s12916-022-02628-2 |
_version_ | 1784822119659470848 |
---|---|
author | Sullivan, Michael K. Carrero, Juan-Jesus Jani, Bhautesh Dinesh Anderson, Craig McConnachie, Alex Hanlon, Peter Nitsch, Dorothea McAllister, David A. Mair, Frances S. Mark, Patrick B. Gasparini, Alessandro |
author_facet | Sullivan, Michael K. Carrero, Juan-Jesus Jani, Bhautesh Dinesh Anderson, Craig McConnachie, Alex Hanlon, Peter Nitsch, Dorothea McAllister, David A. Mair, Frances S. Mark, Patrick B. Gasparini, Alessandro |
author_sort | Sullivan, Michael K. |
collection | PubMed |
description | BACKGROUND: Multimorbidity (the presence of two or more chronic conditions) is common amongst people with chronic kidney disease, but it is unclear which conditions cluster together and if this changes as kidney function declines. We explored which clusters of conditions are associated with different estimated glomerular filtration rates (eGFRs) and studied associations between these clusters and adverse outcomes. METHODS: Two population-based cohort studies were used: the Stockholm Creatinine Measurements project (SCREAM, Sweden, 2006–2018) and the Secure Anonymised Information Linkage Databank (SAIL, Wales, 2006–2021). We studied participants in SCREAM (404,681 adults) and SAIL (533,362) whose eGFR declined lower than thresholds (90, 75, 60, 45, 30 and 15 mL/min/1.73m(2)). Clusters based on 27 chronic conditions were identified. We described the most common chronic condition(s) in each cluster and studied their association with adverse outcomes using Cox proportional hazards models (all-cause mortality (ACM) and major adverse cardiovascular events (MACE)). RESULTS: Chronic conditions became more common and clustered differently across lower eGFR categories. At eGFR 90, 75, and 60 mL/min/1.73m(2), most participants were in large clusters with no prominent conditions. At eGFR 15 and 30 mL/min/1.73m(2), clusters involving cardiovascular conditions were larger and were at the highest risk of adverse outcomes. At eGFR 30 mL/min/1.73m(2), in the heart failure, peripheral vascular disease and diabetes cluster in SCREAM, ACM hazard ratio (HR) is 2.66 (95% confidence interval (CI) 2.31–3.07) and MACE HR is 4.18 (CI 3.65–4.78); in the heart failure and atrial fibrillation cluster in SAIL, ACM HR is 2.23 (CI 2.04 to 2.44) and MACE HR is 3.43 (CI 3.22–3.64). Chronic pain and depression were common and associated with adverse outcomes when combined with physical conditions. At eGFR 30 mL/min/1.73m(2), in the chronic pain, heart failure and myocardial infarction cluster in SCREAM, ACM HR is 2.00 (CI 1.62–2.46) and MACE HR is 4.09 (CI 3.39–4.93); in the depression, chronic pain and stroke cluster in SAIL, ACM HR is 1.38 (CI 1.18–1.61) and MACE HR is 1.58 (CI 1.42–1.76). CONCLUSIONS: Patterns of multimorbidity and corresponding risk of adverse outcomes varied with declining eGFR. While diabetes and cardiovascular disease are known high-risk conditions, chronic pain and depression emerged as important conditions and associated with adverse outcomes when combined with physical conditions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02628-2. |
format | Online Article Text |
id | pubmed-9623942 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96239422022-11-02 The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function Sullivan, Michael K. Carrero, Juan-Jesus Jani, Bhautesh Dinesh Anderson, Craig McConnachie, Alex Hanlon, Peter Nitsch, Dorothea McAllister, David A. Mair, Frances S. Mark, Patrick B. Gasparini, Alessandro BMC Med Research Article BACKGROUND: Multimorbidity (the presence of two or more chronic conditions) is common amongst people with chronic kidney disease, but it is unclear which conditions cluster together and if this changes as kidney function declines. We explored which clusters of conditions are associated with different estimated glomerular filtration rates (eGFRs) and studied associations between these clusters and adverse outcomes. METHODS: Two population-based cohort studies were used: the Stockholm Creatinine Measurements project (SCREAM, Sweden, 2006–2018) and the Secure Anonymised Information Linkage Databank (SAIL, Wales, 2006–2021). We studied participants in SCREAM (404,681 adults) and SAIL (533,362) whose eGFR declined lower than thresholds (90, 75, 60, 45, 30 and 15 mL/min/1.73m(2)). Clusters based on 27 chronic conditions were identified. We described the most common chronic condition(s) in each cluster and studied their association with adverse outcomes using Cox proportional hazards models (all-cause mortality (ACM) and major adverse cardiovascular events (MACE)). RESULTS: Chronic conditions became more common and clustered differently across lower eGFR categories. At eGFR 90, 75, and 60 mL/min/1.73m(2), most participants were in large clusters with no prominent conditions. At eGFR 15 and 30 mL/min/1.73m(2), clusters involving cardiovascular conditions were larger and were at the highest risk of adverse outcomes. At eGFR 30 mL/min/1.73m(2), in the heart failure, peripheral vascular disease and diabetes cluster in SCREAM, ACM hazard ratio (HR) is 2.66 (95% confidence interval (CI) 2.31–3.07) and MACE HR is 4.18 (CI 3.65–4.78); in the heart failure and atrial fibrillation cluster in SAIL, ACM HR is 2.23 (CI 2.04 to 2.44) and MACE HR is 3.43 (CI 3.22–3.64). Chronic pain and depression were common and associated with adverse outcomes when combined with physical conditions. At eGFR 30 mL/min/1.73m(2), in the chronic pain, heart failure and myocardial infarction cluster in SCREAM, ACM HR is 2.00 (CI 1.62–2.46) and MACE HR is 4.09 (CI 3.39–4.93); in the depression, chronic pain and stroke cluster in SAIL, ACM HR is 1.38 (CI 1.18–1.61) and MACE HR is 1.58 (CI 1.42–1.76). CONCLUSIONS: Patterns of multimorbidity and corresponding risk of adverse outcomes varied with declining eGFR. While diabetes and cardiovascular disease are known high-risk conditions, chronic pain and depression emerged as important conditions and associated with adverse outcomes when combined with physical conditions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02628-2. BioMed Central 2022-11-01 /pmc/articles/PMC9623942/ /pubmed/36320059 http://dx.doi.org/10.1186/s12916-022-02628-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Sullivan, Michael K. Carrero, Juan-Jesus Jani, Bhautesh Dinesh Anderson, Craig McConnachie, Alex Hanlon, Peter Nitsch, Dorothea McAllister, David A. Mair, Frances S. Mark, Patrick B. Gasparini, Alessandro The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function |
title | The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function |
title_full | The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function |
title_fullStr | The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function |
title_full_unstemmed | The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function |
title_short | The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function |
title_sort | presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623942/ https://www.ncbi.nlm.nih.gov/pubmed/36320059 http://dx.doi.org/10.1186/s12916-022-02628-2 |
work_keys_str_mv | AT sullivanmichaelk thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT carrerojuanjesus thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT janibhauteshdinesh thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT andersoncraig thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT mcconnachiealex thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT hanlonpeter thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT nitschdorothea thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT mcallisterdavida thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT mairfrancess thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT markpatrickb thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT gasparinialessandro thepresenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT sullivanmichaelk presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT carrerojuanjesus presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT janibhauteshdinesh presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT andersoncraig presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT mcconnachiealex presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT hanlonpeter presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT nitschdorothea presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT mcallisterdavida presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT mairfrancess presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT markpatrickb presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction AT gasparinialessandro presenceandimpactofmultimorbidityclustersonadverseoutcomesacrossthespectrumofkidneyfunction |